Dr. Ligang Xing 邢力刚
Chief Physician
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for common malignancies. Diagnosis and comprehensive treatment of thoracic tumors, including lung and esophageal cancer. Stereotactic body radiation therapy for early-stage lung cancer, functional image-guided radiation therapy, and individualized tumor treatment.
Dr. Xing holds a PhD in Oncology. After graduating in 1996, Dr. Xing completed master’s and doctoral studies at Tianjin Medical University. From 2005 to 2009, Dr. Xing conducted postdoctoral research and clinical training at Memorial Sloan Kettering Cancer Center in New York. Since returning in 2009, Dr. Xing has served as a professor at Shandong University and leads clinical departments at Shandong Cancer Hospital.
Professional roles
- Member, Standing Committee on Stereotactic Radiotherapy and Radiobiology Group, Radiation Oncology Branch, Chinese Medical Association
- Member, Radiation Oncology Professional Committee, China Anti-Cancer Association
- Member and Leader, Radiotherapy Group, Cancer Rehabilitation and Palliative Care Professional Committee, China Anti-Cancer Association
- Vice Chair, Medical Physics and Technology Branch, Shandong Anti-Cancer Association
Name order: in Chinese the family name comes first (Xing Ligang). Papers usually list the name as Ligang Xing or Xing L.
Selected publications
173 papers on PubMed matched by name and affiliation; 43 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2026 (senior author): Development and internal validation of a clinicopathological and CT radiomics based prediction model for extracranial distant metastasis after radical resection in early-stage non-small cell lung cancer. PubMed 42866182
- J Immunother Cancer, 2026 (first author): AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. PubMed 42648750
- Cancer Lett, 2026 (senior author): Stress-inducible circSCLT1 scaffolds HNRNPA1/CSDE1 to amplify IL1B/NF-κB signaling in TNBC via mRNA stabilization, suppressor degradation, and stress granule shielding. PubMed 42092680
- Cancer Lett, 2026 (senior author): IGHG1(+) malignant epithelial Cell-myCAF crosstalk via MIF-CD74/APP-CD74 drives early brain metastasis in NSCLC: Delineated via primary tumor-brain metastasis single-cell and spatial transcriptomics. PubMed 41881335
- Target Oncol, 2026 (first author): Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study. PubMed 42070217
- Eur Radiol, 2026 (senior author): Integrated nomogram for predicting intracranial progression-free survival with EGFR-TKI combined with cranial radiotherapy: a multicenter study. PubMed 41174041
- Precis Radiat Oncol, 2026 (senior author): Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial. PubMed 42022351
- Zhongguo Fei Ai Za Zhi, 2026 (senior author): [Impact of HIF-1α-expressing Cellular Subpopulations on Lymph Node Metastasis and Postoperative Recurrence in Non-small Cell Lung Cancer]. PubMed 41975646
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion